From May 17, 2013 to December 13, 2016, 512 patients with stage I HER2-positive breast cancer were enrolled in the ATEMPT trial and 497 (383 T-DM1, 114 TH) started protocol therapy and were included in this analysis (Fig. 1). This evidence concerns the gene ERBB2 and breast carcinoma.